Nuclear factor-κB- and glucocorticoid receptor α-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome: Evidence for inflammation-induced target tissue resistance to glucocorticoids

G. Umberto Meduri, Muthiah P. Muthiah, Pierluigi Carratu, Mahmoud Eltorky, George P. Chrousos

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

To test the hypothesis that the interaction between nuclear factor-κB (NF-κB) and glucocorticoid receptor α (GRα) is a key pathogenetic mechanism regulating the progression of systemic and pulmonary inflammation in sepsis and acute respiratory distress syndrome (ARDS), we used an ex vivo model of systemic inflammation. Naïve peripheral blood leukocytes (PBL) were exposed to longitudinal (days 1-10) plasma samples from ARDS patients divided into three groups based on physiological improvement and clinical outcome by days 7-10: improvers, nonimprovers-survivors, and nonimprovers-nonsurvivors. In a separate group of nonimprovers-survivors, we correlated the severity of lung histopathology with the intensity of NF-κB and GRα nuclear staining in immunohistochemistry analysis of lung tissue obtained by open lung biopsy. We found that exposure of naïve cells to longitudinal plasma samples led to divergent directions in NF-κB and GRα activation that reflected the severity of systemic inflammation. Plasma samples from improvers with declining cytokine levels over time elicited a progressive increase in all measured aspects of glucocorticoid (GC)-induced GRα-mediated activity (p = 0.0001) and a correspondent reduction in NF-κB nuclear binding (p = 0.0001) and transcription of TNF-α and IL-1β (regulated, GRα-driven response). In contrast, plasma samples from nonimprovers with sustained elevation in cytokine levels over time elicited only a modest longitudinal increase in GC-GRα-mediated activity (p = 0.04) and a progressive increase in NF-κB nuclear binding over time (p = 0.0001) that was most striking in nonsurvivors (dysregulated, NF-κB-driven response). By days 3-5, no overlap was observed between groups for NF-κB and GC-GRα nuclear binding. In immunohistochemistry analyses, lung tissues of patients with severe versus mild ARDS had a higher intensity of NF-κB nuclear staining (13 ± 1.3 vs. 7 ± 2.9; p = 0.01) and a lower ratio of GRα:NF-κB in nuclear staining (0.5 ± 0.2 vs. 1.5 ± 0.2; p = 0.007). In conclusion, we demonstrated that the ability of GC-GRα to downregulate NF-κB activation is critical for the resolution of systemic and pulmonary inflammation in ARDS. The findings provide a rationale for the use of prolonged GC treatment in early ARDS.

Original languageEnglish (US)
Pages (from-to)321-338
Number of pages18
JournalNeuroImmunoModulation
Volume12
Issue number6
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Adult Respiratory Distress Syndrome
Glucocorticoid Receptors
Sepsis
Pneumonia
Inflammation
Glucocorticoids
Lung
Staining and Labeling
Survivors
Immunohistochemistry
Cytokines
Glucocorticoid Receptor Deficiency
Interleukin-1
Leukocytes
Down-Regulation
Biopsy

Keywords

  • Acute respiratory distress syndrome
  • Cytokines
  • Glucocorticoid receptors
  • Glucocorticoids
  • Inflammation
  • Nuclear factor-κB
  • Sepsis

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Immunology

Cite this

Nuclear factor-κB- and glucocorticoid receptor α-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome : Evidence for inflammation-induced target tissue resistance to glucocorticoids. / Meduri, G. Umberto; Muthiah, Muthiah P.; Carratu, Pierluigi; Eltorky, Mahmoud; Chrousos, George P.

In: NeuroImmunoModulation, Vol. 12, No. 6, 03.2006, p. 321-338.

Research output: Contribution to journalArticle

@article{3b8621c2c99746d4b4bc29ea1c483781,
title = "Nuclear factor-κB- and glucocorticoid receptor α-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome: Evidence for inflammation-induced target tissue resistance to glucocorticoids",
abstract = "To test the hypothesis that the interaction between nuclear factor-κB (NF-κB) and glucocorticoid receptor α (GRα) is a key pathogenetic mechanism regulating the progression of systemic and pulmonary inflammation in sepsis and acute respiratory distress syndrome (ARDS), we used an ex vivo model of systemic inflammation. Na{\"i}ve peripheral blood leukocytes (PBL) were exposed to longitudinal (days 1-10) plasma samples from ARDS patients divided into three groups based on physiological improvement and clinical outcome by days 7-10: improvers, nonimprovers-survivors, and nonimprovers-nonsurvivors. In a separate group of nonimprovers-survivors, we correlated the severity of lung histopathology with the intensity of NF-κB and GRα nuclear staining in immunohistochemistry analysis of lung tissue obtained by open lung biopsy. We found that exposure of na{\"i}ve cells to longitudinal plasma samples led to divergent directions in NF-κB and GRα activation that reflected the severity of systemic inflammation. Plasma samples from improvers with declining cytokine levels over time elicited a progressive increase in all measured aspects of glucocorticoid (GC)-induced GRα-mediated activity (p = 0.0001) and a correspondent reduction in NF-κB nuclear binding (p = 0.0001) and transcription of TNF-α and IL-1β (regulated, GRα-driven response). In contrast, plasma samples from nonimprovers with sustained elevation in cytokine levels over time elicited only a modest longitudinal increase in GC-GRα-mediated activity (p = 0.04) and a progressive increase in NF-κB nuclear binding over time (p = 0.0001) that was most striking in nonsurvivors (dysregulated, NF-κB-driven response). By days 3-5, no overlap was observed between groups for NF-κB and GC-GRα nuclear binding. In immunohistochemistry analyses, lung tissues of patients with severe versus mild ARDS had a higher intensity of NF-κB nuclear staining (13 ± 1.3 vs. 7 ± 2.9; p = 0.01) and a lower ratio of GRα:NF-κB in nuclear staining (0.5 ± 0.2 vs. 1.5 ± 0.2; p = 0.007). In conclusion, we demonstrated that the ability of GC-GRα to downregulate NF-κB activation is critical for the resolution of systemic and pulmonary inflammation in ARDS. The findings provide a rationale for the use of prolonged GC treatment in early ARDS.",
keywords = "Acute respiratory distress syndrome, Cytokines, Glucocorticoid receptors, Glucocorticoids, Inflammation, Nuclear factor-κB, Sepsis",
author = "Meduri, {G. Umberto} and Muthiah, {Muthiah P.} and Pierluigi Carratu and Mahmoud Eltorky and Chrousos, {George P.}",
year = "2006",
month = "3",
doi = "10.1159/000091126",
language = "English (US)",
volume = "12",
pages = "321--338",
journal = "NeuroImmunoModulation",
issn = "1021-7401",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Nuclear factor-κB- and glucocorticoid receptor α-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome

T2 - Evidence for inflammation-induced target tissue resistance to glucocorticoids

AU - Meduri, G. Umberto

AU - Muthiah, Muthiah P.

AU - Carratu, Pierluigi

AU - Eltorky, Mahmoud

AU - Chrousos, George P.

PY - 2006/3

Y1 - 2006/3

N2 - To test the hypothesis that the interaction between nuclear factor-κB (NF-κB) and glucocorticoid receptor α (GRα) is a key pathogenetic mechanism regulating the progression of systemic and pulmonary inflammation in sepsis and acute respiratory distress syndrome (ARDS), we used an ex vivo model of systemic inflammation. Naïve peripheral blood leukocytes (PBL) were exposed to longitudinal (days 1-10) plasma samples from ARDS patients divided into three groups based on physiological improvement and clinical outcome by days 7-10: improvers, nonimprovers-survivors, and nonimprovers-nonsurvivors. In a separate group of nonimprovers-survivors, we correlated the severity of lung histopathology with the intensity of NF-κB and GRα nuclear staining in immunohistochemistry analysis of lung tissue obtained by open lung biopsy. We found that exposure of naïve cells to longitudinal plasma samples led to divergent directions in NF-κB and GRα activation that reflected the severity of systemic inflammation. Plasma samples from improvers with declining cytokine levels over time elicited a progressive increase in all measured aspects of glucocorticoid (GC)-induced GRα-mediated activity (p = 0.0001) and a correspondent reduction in NF-κB nuclear binding (p = 0.0001) and transcription of TNF-α and IL-1β (regulated, GRα-driven response). In contrast, plasma samples from nonimprovers with sustained elevation in cytokine levels over time elicited only a modest longitudinal increase in GC-GRα-mediated activity (p = 0.04) and a progressive increase in NF-κB nuclear binding over time (p = 0.0001) that was most striking in nonsurvivors (dysregulated, NF-κB-driven response). By days 3-5, no overlap was observed between groups for NF-κB and GC-GRα nuclear binding. In immunohistochemistry analyses, lung tissues of patients with severe versus mild ARDS had a higher intensity of NF-κB nuclear staining (13 ± 1.3 vs. 7 ± 2.9; p = 0.01) and a lower ratio of GRα:NF-κB in nuclear staining (0.5 ± 0.2 vs. 1.5 ± 0.2; p = 0.007). In conclusion, we demonstrated that the ability of GC-GRα to downregulate NF-κB activation is critical for the resolution of systemic and pulmonary inflammation in ARDS. The findings provide a rationale for the use of prolonged GC treatment in early ARDS.

AB - To test the hypothesis that the interaction between nuclear factor-κB (NF-κB) and glucocorticoid receptor α (GRα) is a key pathogenetic mechanism regulating the progression of systemic and pulmonary inflammation in sepsis and acute respiratory distress syndrome (ARDS), we used an ex vivo model of systemic inflammation. Naïve peripheral blood leukocytes (PBL) were exposed to longitudinal (days 1-10) plasma samples from ARDS patients divided into three groups based on physiological improvement and clinical outcome by days 7-10: improvers, nonimprovers-survivors, and nonimprovers-nonsurvivors. In a separate group of nonimprovers-survivors, we correlated the severity of lung histopathology with the intensity of NF-κB and GRα nuclear staining in immunohistochemistry analysis of lung tissue obtained by open lung biopsy. We found that exposure of naïve cells to longitudinal plasma samples led to divergent directions in NF-κB and GRα activation that reflected the severity of systemic inflammation. Plasma samples from improvers with declining cytokine levels over time elicited a progressive increase in all measured aspects of glucocorticoid (GC)-induced GRα-mediated activity (p = 0.0001) and a correspondent reduction in NF-κB nuclear binding (p = 0.0001) and transcription of TNF-α and IL-1β (regulated, GRα-driven response). In contrast, plasma samples from nonimprovers with sustained elevation in cytokine levels over time elicited only a modest longitudinal increase in GC-GRα-mediated activity (p = 0.04) and a progressive increase in NF-κB nuclear binding over time (p = 0.0001) that was most striking in nonsurvivors (dysregulated, NF-κB-driven response). By days 3-5, no overlap was observed between groups for NF-κB and GC-GRα nuclear binding. In immunohistochemistry analyses, lung tissues of patients with severe versus mild ARDS had a higher intensity of NF-κB nuclear staining (13 ± 1.3 vs. 7 ± 2.9; p = 0.01) and a lower ratio of GRα:NF-κB in nuclear staining (0.5 ± 0.2 vs. 1.5 ± 0.2; p = 0.007). In conclusion, we demonstrated that the ability of GC-GRα to downregulate NF-κB activation is critical for the resolution of systemic and pulmonary inflammation in ARDS. The findings provide a rationale for the use of prolonged GC treatment in early ARDS.

KW - Acute respiratory distress syndrome

KW - Cytokines

KW - Glucocorticoid receptors

KW - Glucocorticoids

KW - Inflammation

KW - Nuclear factor-κB

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=33645557190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645557190&partnerID=8YFLogxK

U2 - 10.1159/000091126

DO - 10.1159/000091126

M3 - Article

AN - SCOPUS:33645557190

VL - 12

SP - 321

EP - 338

JO - NeuroImmunoModulation

JF - NeuroImmunoModulation

SN - 1021-7401

IS - 6

ER -